Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DS-1062a · 1 trial · 1 indication
ORR is defined as the proportion of participants with a best overall response of confirmed complete response (CR) or confirmed partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
| Arm | Type | Description |
|---|---|---|
| DS-1062a 6.0 mg/kg | EXPERIMENTAL | Participants will receive 6.0 mg/kg of DS-1062a |
| Name | Type | Description |
|---|---|---|
| DS-1062a | DRUG | DS-1062a will be administered as an intravenous (IV) infusion once every 3 weeks |
Inclusion Criteria: Participants eligible for inclusion in the study must meet all inclusion criteria for this study. * Sign and date the inform consent form (ICF) prior to the start of any study- specific qualification procedures. * Adults ≥18 years (if the legal age of consent is \>18 years old,...
Top 20 of 84 competitors
DS-1062a is an investigational small molecule being studied for the treatment of non-small cell lung cancer (NSCLC). It is currently in Phase 2 clinical development and is not yet approved by regulatory authorities. The drug is being evaluated in patients with advanced or metastatic NSCLC who have actionable genomic alterations.
DS-1062a is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker symbol AZN. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational oncology drug.
DS-1062a is currently in Phase 2 clinical development. It is an investigational drug, meaning it has not yet received regulatory approval and is still being studied in clinical trials. The drug is being evaluated for the treatment of non-small cell lung cancer.
DS-1062a has been studied in a Phase 2 clinical trial with the identifier NCT04484142, titled 'Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)'. This trial enrolled 137 participants and has been completed.
No, DS-1062a is the drug being studied, while TROPION-Lung05 is the name of the clinical trial evaluating it. The trial, identified as NCT04484142, is a Phase 2 study that has been completed and enrolled 137 patients with non-small cell lung cancer.